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Abstract
Background: Pancreatic neuroendocrine tumors (PNETs) are rare pancreatic neoplasms. About 40–80% of patients
with PNET are metastatic at presentation, usually involving the liver (40–93%). Liver metastasis represents the most
significant prognostic factor. The aim of this study is to present an up-to-date review of treatment options for
patients with liver metastases from PNETs.
Methods: A systematic literature search was performed using the PubMed database to identify all pertinent studies
published up to May 2018.
Results: The literature search evaluated all the therapeutic options for patients with liver metastases of PNETs,
including surgical treatment, loco-regional therapies, and pharmacological treatment. All the different treatment
options showed particular indications in different presentations of liver metastases of PNET. Surgery remains the
only potentially curative therapeutic option in patients with PNETs and resectable liver metastases, even if relapse
rates are high. Efficacy of medical treatment has increased with advances in targeted therapies, such as everolimus
and sunitinib, and the introduction of radiolabeled somatostatin analogs. Several techniques for loco-regional
control of metastases are available, including chemo- or radioembolization.
Conclusions: Treatment of patients with PNET metastases should be multidisciplinary and must be personalized
according to the features of individual patients and tumors.
Background
Pancreatic neuroendocrine tumors (PNETs) are rare
tumors, representing 1.3 to 10.0% of all pancreatic
tumors. Annual incidence of PNET is estimated to be
3.65/10,000 people per year [1–3]. Due to the recent
widespread use of diagnostic techniques, there is a
dramatic increase in the incidence of PNETs [4]. No
differences in PNET incidence are reported between
men and women. Peak of PNET’s diagnosis occurs
between 30 and 60 years [5]. PNETs may be classified as
functioning or non-functioning tumors. Functioning
PNETs are characterized by secretion of one or more
biologically active peptides, inducing specific clinical
syndromes. Secreting products include insulin, gastrin,
glucagon, somatostatin, and vasoactive intestinal peptide
(VIP). Non-functioning PNETs may secrete peptides,
such as chromogranin A and neurotensin, and may be
asymptomatic [6]. Diagnosis of non-functioning PNETs
is usually late for the absence of specific symptoms;
therefore, probability of malignancy is higher if com-
pared with functioning PNETs and reported survival is
as low as 30% [7]. PNETs are also characterized by the
expression of somatostatin receptors. They may be a
component of several syndromes, such as Von Hippel-
Lindau syndrome, multiple endocrine neoplasia syn-
dromes, or neurofibromatosis type I [6]. Metastases are
detected at diagnosis in about 40–80% of patients with
PNET [8]. The more frequent sites are the liver (40–93%),
followed by the bone (12–20%) and lungs (8%–10%) [8].
The presence of liver metastases also has a negative impact
on the prognosis [9, 10], and the extension of PNET liver
metastases is correlated to long-term survival [11, 12]. The
development of liver metastasis is related to the histo-
logical tumor type and to the site of the primary tumor
[13]. Other factors with a strong prognostic impact are as
* Correspondence: giuseppe.nigri@uniroma1.it
1Department of Medical and Surgical Science and Translational Medicine, St.
Andrea Hospital Rome, Sapienza University of Rome, Via di Grottarossa 1035,
00189 Rome, Italy
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Nigri et al. World Journal of Surgical Oncology  (2018) 16:142 
https://doi.org/10.1186/s12957-018-1446-y
follows: size of the primary tumor, mitotic index, vascular
and lymphatic invasion, proliferative activity, metabolite
serum concentration, and cellular atypias [14]. Treatment
of metastatic PNETs is complex and requires multidiscip-
linary expertise including medical, interventional, and sur-
gical specialties.
Furthermore, multidisciplinary management of meta-
static PNETs is in constant evolution. Therefore, it is im-
portant to periodically review the recent acquisition, to
provide up-to-date and comprehensive data to clinicians.
This review, based on a systematic literature search,
aims to discuss metastatic PNET’s management from
clinical, biochemical, and radiological diagnosis to treat-
ment, focusing on all treatment possibilities in a multi-
disciplinary approach.
Methods
Search strategy and study selection
A systematic literature search was performed using the
PubMed database, in order to identify all studies published
up to May 2018 reporting data on patients treated for liver
metastases from pancreatic neuroendocrine tumors
(PNETs) undergoing surgical treatment, including liver
resection or liver transplantation, interventional proce-
dures, or medical treatment. The following MeSH search
terms were used: “liver” OR “hepatic,” “metastasis OR
metastases,” and “pancreatic neuroendocrine tumor” OR
“PNET.” The “related articles” function was used to
broaden the search, and all the abstracts and citations of
all returned studies were reviewed. The full text was
examined, in case of any doubt after reading the article’s
abstract. Non-English language studies were excluded.
Two authors (NP, LM) examined the articles to establish
the inclusion in this review.
Results
Search results
Initial search retrieved 10,135 articles. Titles and abstract
were analyzed to identify 476 relevant publications. Of
them, 116 articles were retained to review the current
literature on this topic [1–116]. PRISMA flow diagram is
showed in Fig. 1. The majority of them were observa-
tional studies. Meta-analyses and review were the second
most represented group.
Diagnosis and staging
The main factors determining the clinical manifestation of
PNET liver metastases are the liver tumor load and the
degree of endocrine activity. Usually, patients may remain
asymptomatic for a long time. Development of carcinoid
syndrome is possible, such as abdominal pain or discom-
fort. Liver malfunction or failure is a rare occurrence, even
in the case of extensive liver involvement [15].
Diagnosis is done on the basis of biochemical labora-
tory examinations, including specific tumor markers,
and on radiological imaging.
Plasmatic chromogranin A is a widely accepted tumor
marker, used for diagnostic and prognostic purposes and
to evaluate the response to treatment. Its specificity and
sensitivity depend on tumor type and volume [16].
5-Hydroxyindoleacetic acid is a urinary metabolite of
serotonin, which may be increased in patients with
metastatic PNET, and it is used for diagnosis and
follow-up [17]. Other biochemical markers are less used
in clinical practice, including urine serotonin, synapto-
physin, neuron-specific enolase, parathyroid hormone-
related protein, calcitonin, pancreatic polypeptide, and
human chorionic gonadotropin [18]. On the other hand,
functioning tumors secrete hormones related to a spe-
cific clinical syndrome, such as insulin (insulinoma), glu-
cagon (glucagonoma, confirmed by serum glucagon level
> 1000 pg/mL), gastrin (elevated serum gastrin and gas-
tric acids), and vasoactive intestinal polypeptide (vipoma,
VIP values > 200 pg/mL) [19–21].
Somatostatin receptor scintigraphy is frequently used
for PNET imaging. Advantages include the acquisition
of whole-body images with possible visualization of the
primary tumor and metastases, and the possibility to
identify the patients who are candidates for somatostatin
receptor-based radiotherapy [22].
Positron emission tomography (PET) with DOTATOC
or DOTANOC associated with the positron emitter
Gallium 68 allows even better sensitivity (up to 30%
higher than standard imaging) [23].
CT scan has wide diffusion and is associated with
sensitivity rates up to 94–100% [24], especially if com-
bined with PET [25]. Magnetic resonance imaging is also
used in the staging and evaluation of disease progression,
for its ability to detect lesions in the liver, combined with
reduction of excessive radiation burden [26].
Several staging systems exist for PNET classification.
The WHO, European Neuroendocrine Tumor Society
(ENETS), and American Joint Committee on Cancer
(AJCC) have proposed each a staging system [27–29].
The WHO classification is based on cellular proliferation
(measured as mitotic count and Ki-67 expression), as
shown in Table 1 [27]. The ENETS staging system
(Table 2) is based on TNM classification [28], and the
AJCC staging system (reported in Table 3) is developed
from the TNM staging system for pancreatic adenocar-
cinoma [29].
Treatment options for metastatic PNETs
The therapeutic options for patients with liver metastases
from pancreatic neuroendocrine tumors include surgical
treatment, loco-regional therapies, and pharmacological
treatment. The decision of the treatment strategy is based
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on the analysis of patient performance status and comor-
bidities, on accurate tumor staging, and on evaluation of
prognostic factors. Surgery represents the only potentially
curative therapy when the disease is completely resectable.
In patients with advanced and unresectable disease, how-
ever, the therapeutic goal is lengthening survival with the
best possible quality of life and palliation of symptoms,
using a multidisciplinary approach.
Liver surgery for pancreatic neuroendocrine liver
metastases
Surgery remains the treatment of choice in selected pa-
tients with PNETs and resectable liver metastases, because
it may provide cure. Liver resection for neuroendocrine
metastases is associated to long-term survival advantages
and disease control [30, 31]. Surgery may have either cura-
tive intent, when complete resection is possible, or pallia-
tive intent, when the majority of the tumor burden is
removed to control the symptoms of the disease. Due to
the rarity of the disease, the majority of published articles
on surgical treatments of liver metastases from neuroen-
docrine tumors report data on neuroendocrine metastases
from several primary sites (e.g., GEP-NET metastases).
Potentially curative surgery
Potentially curative surgery is possible in only 10–25%
of patients with liver metastases [32]. Bilobar metastases
may be treated with two-step resections, and preopera-
tive portal vein embolization may be used to induce
hypertrophy of the left liver lobe, as in colorectal liver
metastases [33]. Concurrent or staged resection of the
primary lesion and liver metastases may be considered,
if surgery can remove most of the metastatic tumor
volume (> 90%). Criteria helping to select patients for
surgery include the presence of well-differentiated G1/
G2 tumors, absence of distant lymph node metastasis,
absence of extrahepatic metastasis, absence of diffuse
peritoneal metastasis, and absence of right cardiac dys-
function [34].
Fig. 1 PRISMA diagram showing the systematic search results
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Unfortunately, tumor relapse in the first 2 years after
resection is reported in the majority of patients [35], and
a relapse rate of up to 80% at 5 years has been shown
[36–50]. Despite the elevated percentage of tumor recur-
rence, 5-year survival rates approach 85%, which is in
favor of an aggressive surgical approach. Morbidity and
mortality of liver resection are acceptable with the ad-
vancement in preoperative management and surgical
techniques, and are comparable to liver resection for
other diseases [36–51].
No randomized trials have compared the results of
liver resection to other non-surgical treatments for
PNET liver metastases [52]. However, retrospective com-
parisons of the outcomes of patients treated with med-
ical therapies or palliative care or surgery highlight the
advantages of surgical treatment. Survival outcomes of
curative surgery are better than those of loco-regional
therapies, such as liver chemoembolization, as reported
by Elias et al., detecting a 5-year survival rate of 71% for
47 patients who underwent partial hepatectomy versus
31% for 65 patients treated with chemoembolization
[41]. Furthermore, Tao et al. demonstrated that debulk-
ing surgery improves the effect of the subsequent
loco-regional treatment [49].
The presence of a single liver metastasis is associated
with better survival, as shown by Frilling et al. [32]. In
cases of synchronous metastases, simultaneous resection
of the primitive tumor and hepatectomy has been re-
ported, with acceptable postoperative morbi-mortality.
Sarmiento et al. treated 23 patients who underwent
synchronous pancreatic and liver resection. Postoperative
mortality was 0%, the major complication rate 18%, and
the 5-year survival was as high as 71% [42]. Bonney et al.
showed comparable results, with morbidity of 25%, one
death in the postoperative period, and a 5-year survival of
70% [48].
Cytoreductive surgery
Cytoreductive surgery in patients with PNET liver me-
tastases aims to increase survival, control symptoms,
and improve quality of life. Cytoreductive liver resec-
tions are indicated in patients with symptoms not control-
lable with medical or hormonal treatment. It consists of
resection of more than 90% of the tumor mass [53, 54].
Recently, Morgan et al. proposed a threshold of > 70%,
with the argument that postoperative results are compar-
able between debulking > 70, > 90, and 100% [55]. Reduc-
tion in tumor volume may reduce the immunosuppressive
effects of the tumor and decrease the probability of devel-
opment of further metastases. Surgical debulking is effi-
cient for the symptoms in the majority of patients with
functioning PNETs [44–47, 56]. Combined approaches in-
cluding aggressive surgical resection, ablative therapies,
and chemotherapy may be employed to obtain cytoreduc-
tion of the tumor [57].
Symptomatic benefits are achieved in 80–90% of pa-
tients submitted to curative liver resections [12, 42, 54].
The mean duration of the response to the surgical
debulking is correlated with the amount of tumor re-
moved and to the normalization of tumor markers [12].
Recurrence of symptoms occurs in the first 5 years after
Table 1 WHO grading system for PNETs [27]
Grade 1 (G1) Grade 2 (G2) Grade 3 (G3)
Ki-67 index < 3% 3–20% > 20%
Mitotic count < 2/10 HPF 2–20/10 HPF > 20/10 HPF
Differentiation Well differentiated Moderately differentiated Poorly differentiated
WHO World Health Organization, PNETs pancreatic neuroendocrine tumors, HPF high-power field
Table 2 ENETS staging system for PNET [28]
Stage T N M
I T1 N0 M0
IIA T2 N0 M0
IIB T3 N0 M0
IIIA T4 N0 M0
IIIB Any T N1 M0
IV Any T Any N M1
ENETS European Neuroendocrine Tumor Society, PNET pancreatic
neuroendocrine tumors, T1 tumors < 2 cm limited to the pancreas, T2 2–4 cm
limited to the pancreas, T3 > 4 cm limited to the pancreas or invading the
duodenum or common bile duct, T4 tumor invading adjacent structures or
large vessels, N0 no regional lymph node metastases, N1 regional lymph node
metastases, M0 no distant metastases, M1 distant metastases
Table 3 AJCC staging system for PNETs (7th edition, 2010) [29]
Stage T N M
0 Tis N0 M0
IA T1 N0 M0
IB T2 N0 M0
IIA T3 N0 M0
IIB T1–3 N1 M0
III T4 Any N M0
IV Any T Any N M1
AJCC American Joint Committee on Cancer, PNET pancreatic neuroendocrine
tumors, T1 < 2 cm limited to the pancreas, T2 > 2 cm limited to the pancreas,
T3 tumor extends beyond the pancreas but not involving the celiac axis or
SMA, T4 tumor involves celiac axis or SMA, N0 no regional lymph node
metastases, N1 regional lymph node metastases, M0 no distant metastases, M1
distant metastases
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surgery in the majority of patients [42]. Reported rates
of complications and mortality are considered acceptable
[12, 42, 44–46, 58–60]. If > 75% of the liver parenchyma
is involved, prognosis is considered unfavorable and sur-
gical treatment should be avoided [43].
Liver transplantation
Liver transplantation represents a potentially curative
treatment for liver metastases from PNETs. Early results
are promising, and future development of this strategy is
possible. Orthotropic liver transplantation (OLT) has been
proposed for PNETs for two reasons: the less-aggressive
biological behavior of neuroendocrine metastases com-
pared to other metastases and the low percentage of
patients with PNET liver metastases candidates for R0
liver resections [8, 61]. However, this indication is re-
stricted because of the lack of donors and the perplexity
in allocation of organs to oncological patients. Further-
more, the first studies on liver transplantation for meta-
static neuroendocrine tumors were not concordant and
reported mediocre results. This was due in part to the lack
of valid and homogeneous selection criteria [61–67].
Liver transplantation is considered reasonable if
expected overall survival is more than 70% at 5 years
and disease-free survival is more than 50% [8]. The best
candidates in this setting are young patients (< 50 years
old), with no extrahepatic lesions, well-differentiated
tumors, and low levels of Ki-67. Mazzaferro et al. pro-
posed the following inclusion criteria [8]: diagnosis of
low-grade NET confirmed by histological examination
(with low expression of Ki-67), location of the primary
tumor in an anatomic area tributary to the portal vein,
primary tumor already resected with clear margins, <
50% of liver involvement, stable disease during 6 months
before OLT, and age < 55 years. Recently, a comprehen-
sive review showed encouraging 5-year survival after
OLT for NET, but a high recurrence rate [68]. So at
present, liver transplantation does not represent routine
care in this setting and is considered investigational
and allowed in the setting of clinical studies [69].
Another debated point is the indication for primary
tumor resection in patients with unresectable metastatic
disease. Recent retrospective studies [70] and a meta-
analysis showed that the palliative resection of the pri-
mary tumor in patients with PNETs and unresectable
liver metastases may increase long-term survival. The
meta-analysis by Zhou and colleagues included 10 stud-
ies, with a total of 1226 patients undergoing primary
tumor resection and 1623 patients who did not have sur-
gery [71]. The results of the meta-analysis showed a sig-
nificantly longer survival in patients who had surgical
resection of the primary tumor (at 5 years, 35.7–83%
surviving patients in the surgical group versus 5.4–50%
in the non-surgical group) [71].
Liver-directed therapies
Liver-directed therapies used to treat PNET metastases
include radiofrequency ablation (RFA), cryoablation,
alkalization, transarterial embolization (TAE), and trans-
arterial chemoembolization (TACE) [72].
Ablative therapies
RFA is a safe technique, generally used to treat unresect-
able metastases smaller than 5 cm. Associated morbidity
is low and mainly consists in bleeding and abscess for-
mation [73]. RFA is effective to treat symptoms related
to liver metastases and hormone secretion, even if the
tumor size represents a limiting factor. RFA is less useful
for tumors > 5 cm, even if repeat ablation sessions are
possible [37]. The location of the lesion should be con-
sidered, because RFA may be contraindicated for liver
metastases near to vital structures or at the liver surface.
Cryotherapy is another suitable option, and percutan-
eous ethanol injection is an alternative in cases where
tumors are close to vital structures or vessels [74].
Hepatic arterial embolization
The rationale of hepatic transarterial embolization is
that neuroendocrine metastases receive most of their
blood supply from the hepatic artery, whereas normal
liver parenchyma gets 75% of its blood supply from the
portal vein flow [75]. Both TAE and TACE effectively
reduce tumor size and improve patients’ symptoms. No
randomized studies comparing the two techniques have
been published nor studies comparing embolization
techniques with cytoreductive surgery in the palliative
segment. Embolization is not associated with risks of
tumor dissemination (this is an advantage compared to
RFA). During TAE, embolization is performed using
lipiodol, gem foam particles, polyvinyl alcohol foam, or
bland microspheres, whereas for TACE, chemotherapeu-
tic agents are added, leading to an intra-tumoral drug
concentration over 20 times greater than those obtained
with systemic administration. Furthermore, both pro-
voke tumor ischemia. Commonly used drugs are doxo-
rubicin, melphalan, and streptozocin. Minor side effects
of the procedure are fever, leukocytosis, abdominal pain,
and liver cytolysis.
Morbidity rate is low, even if serious complications,
such as liver abscess, gallbladder necrosis, bowel ische-
mia, pleural effusion, and hepatic failure, have been
reported [76]. Tumor response is objectivized in 25–
86% of cases, and the duration of the response ranges
from 6 to 45 months [77–79]. In a recent series, clinical
improvement and tumor response were observed in
95% of patients, with median time to tumor progression
of 14 ± 16 months and median overall survival of 22 ±
18 months [80].
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Both TAE and TACE are considered for palliation in
unresectable tumors, especially for functioning tumors
with symptoms not controlled by medical therapy. Con-
traindications of TAE and TACE include portal vein oc-
clusion, insufficient liver reserve, and poor performance
status. In patients with previous pancreaticoduodenect-
omy, transarterial therapies are generally contraindicated,
due to higher risks of post-procedure morbidity.
Liver-directed therapies may also be proposed in pa-
tients with extrahepatic metastases to control liver
disease and symptoms [80–83].
Selective internal radiotherapy (SIRT) consists of
embolization with 90Yttrium microsphere, a beta-emitter
that results in tissue penetration of 2.5 mm. Published
data on SIRT show a response rate of 55% and
stabilization of the disease in 32% of cases [84–87]. More
recently, an overall disease control rate of 88.9% at
3 months after therapy has been demonstrated, confirm-
ing its effectiveness in treating unresectable PNET liver
metastases [30]. SIRT is contraindicated in cases of aber-
rant vessels with shunt to the gastrointestinal tract, com-
promised portal veins, and inadequate liver functional
reserve to avoid potentially serious complications.
Medical therapy
Medical therapy is indicated for advanced unresectable
PNETs and includes drugs acting on hormone receptors,
conventional chemotherapy, and molecular target ther-
apy [88].
Somatostatin analogs (SSAs) act on somatostatin recep-
tors and are effective in controlling hormonal secretion
and tumor growth. Either functioning or non-functioning
PNETs express at least one of the five subtypes of somato-
statin receptor (SSTR). Different SSAs have specific affin-
ity for different SSTRs [89]. Octreotide and lanreotide
have high affinity for SSTR2 and bind to SSTR5, whereas
the recent analog pasireotide binds with high affinity to
SSTR1, SSTR2, SSTR3, and SSTR5 [89, 90]. Several stud-
ies and a randomized controlled trial advocate the use of
SSAs to control tumor growth and symptoms in this set-
ting [89, 91, 92]. The randomized controlled trial by Rinke
et al. demonstrated that long-acting octreotide is effica-
cious on both functioning and non-functioning tumors,
with a 66.7% reduction in the risk of disease progression
in treated patients compared to patients taking a placebo
[92]. However, these results referred to a specific setting
of patients with limited liver involvement (≤ 10%) and
already resected primary tumors. Further randomized
trials to confirm these data in other patient categories are
needed. The CLARINET (Controlled Study on Lanreotide
Antiproliferative Response in NETs) study is an ongoing
trial, which aims to evaluate the efficacy of lanreotide in
patients with well or moderately differentiated, non-func-
tioning NETs with Ki-67% expression < 10% [93]. A
number of other previous studies have advocated for the
efficacy of SSAs on PNETs, with tumor stabilization re-
ported in 40–80% of patients and objective tumor re-
sponse (demonstrated by reduction of tumor volume) in
about 10% of patients [94–96]. If treatment with SSAs at
standard dose fails, management options include shorten-
ing of SSA administration intervals or augmentation of
SSA dosage. For patients with progressing tumors, admin-
istration of SSAs every 21 days was compared to adminis-
tration every 28 days, demonstrating a longer time to
progression, better symptom control, and reduction in the
serum level of tumor markers in the group with the
shorter interval of administration [97]. SSAs are well toler-
ated and have generally mild side effects. Long-term side
effects include gallbladder lithiasis (1%), glucose intoler-
ance or diabetes, and steatorrhea [96].
Alpha-interferon may be associated with somatostatin
analogs for palliation or hormonal symptoms, with tumor
stabilization occurring in 30–80% of patients. Reduction
of tumor volume occurs only in a small percentage of pa-
tients [98]. Side effects are frequent and include flu-like
symptoms (80–90%), anorexia, weight loss, fatigue, bone
marrow or liver toxicity, and autoimmune disorders.
Systemic chemotherapy is only indicated for advanced
and unresectable PNETs and may consist in the administra-
tion of various cytotoxic agents, such as streptozotocin, cis-
platin, dacarbazine, doxorubicin, and 5-fluorouracil [99].
The efficacy of the combination of streptozotocin with
5-fluorouracil (5-FU) and/or epirubicin in treating G1/G2
pNENs has been demonstrated, with a reported objective
response rate of 20–45% [100, 101]. Alternative options in-
clude temozolomide alone or in combination with capecita-
bine, leading to a partial response rate of 70%, median
progression-free survival (PFS) of 18 months, and 2-year
survival of 92% in cases of metastatic, well-differentiated
PNETs [102]. For high-grade tumors with poor differenti-
ation, platinum-based regimes are preferred. Response rates
of 42–67% have been obtained combining cisplatin and eto-
poside [103]. Saif et al. suggested the use of capecitabine/
temozolomide (CAPTEM) regimen in patients with failure
of the previous therapy [104].
Targeted therapies
Recent advancements in comprehension of the pathogenesis
and molecular mechanisms of PNETs have allowed the de-
velopment and introduction of novel targeted therapies in
the clinical practice. The mTOR protein is a serine/threo-
nine kinase, and a key component of a cellular pathway
playing an important role in the regulation of cell growth
and proliferation. mTOR is upregulated in several tumors,
including PNETs [105]. Everolimus is an mTOR inhibitor
that has shown efficacy in phase II and phase III studies in
patients with PNETs [106]. The RADIANT3 study random-
ized patients with advanced PNET into two groups: patients
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receiving everolimus (10 mg per day) (group 1) and patients
receiving a placebo (group 2). Patients treated with everoli-
mus had significantly longer PFS (11 versus 4.6 months)
than patients receiving placebo [107]. Side effects include
stomatitis, rash, fatigue, diarrhea, hyperglycemia, and
hematological and pneumological effects.
Sunitinib is an inhibitor of the tyrosine kinases PDGFR,
VEGFR-1, VEGFR-2, c-KIT, and FLIT3 [108, 109]. The ra-
tionale for its use in the treatment of PNETs is the fre-
quent overexpression of VEGF or VEGFR by these
tumors. A phase III study comparing sunitinib to a pla-
cebo has shown a response rate of 9.3% and an increased
PFS of 11.1 months in the group treated with sunitinib
(versus PFS of 5.5 months in the placebo group) [110].
Side effects of sunitinib include diarrhea, nausea, vomit-
ing, asthenia, fatigue, hypertension, and neutropenia. Ray-
mond et al. reported a partial tumor response in 42% of
patients and stable disease in 33% of patients after treat-
ment with 37.5 mg/day of sunitinib [110].
Radiolabeled somatostatin analogs represent a new
treatment option in patients with strong radiotrace uptake
on SRS [111]. Peptide receptor radionuclide therapy
(PRRT) with radiolabeled SSAs allows administration of
targeted radiotherapy to the tumor tissue and its metasta-
ses [112]. The most used radiolabels are 90Yttrium, a
high-energy beta-particle emitter, and 177Lutetium, which
emits beta particles and gamma rays. Even if complete
tumor response is rare with this treatment (0–6%), results
are encouraging, with partial tumor regression in 7–37%
of patients and stabilization in 42–86% using 90Yttrium-
labeled SSAs [112–114]. 177Lutetium octreotate was used
on 510 patients, 40% of whom had PNETs, and partial
response was observed in 28% of cases, with stabilization
of the disease in 35% [115, 116]. PRRT is a promising
therapeutic option, even if still investigational.
Conclusions
Therapeutic options for patients with liver metastases
from pancreatic neuroendocrine tumors include surgery,
loco-regional therapies, and medical therapies. Surgery
represents the only potentially curative treatment and
should be proposed for resectable patients, even if re-
lapse rates are high. Efficacy of medical treatment has
increased with advances in targeted therapies, such as
everolimus and sunitinib, and with the introduction of
radiolabeled somatostatin analogs. Several techniques for
loco-regional control of metastases are available, includ-
ing chemo- or radioembolization. Treatment of patients
with pancreatic neuroendocrine metastases should be
multidisciplinary, must be personalized according to the
features of individual patients and tumors, and should
take into account all possible options in order to provide
the best possible results in terms of survival and quality
of life.
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